-
FDA approves COVID-19 antiviral Xocova as PEP. But will it be accessible?
Shionogi, the Japanese company that makes Xocova (ensitrelvir), said the post-exposure prophylaxis drug will be available in mid-July in the U.S. and will have a list price of $1,400. But its impact will hinge on how easily people can access it, experts say. Read more…
Recent articles
Get the latest Long COVID news and commentary
Processing…
Success! You're on the list.
Whoops! There was an error and we couldn't process your subscription. Please reload the page and try again.
Check out our weekly podcast, Still Here
Spotify
Apple Podcasts
PocketCasts
iHeartRadio
RSS
Policy & Advocacy
-
Maryland considers Long COVID innovation bill
-
HHS hosts event and announces new initiatives for Lyme disease, but advocates are skeptical about follow-through
-
“Medically neglected” and “structurally erased”: International network appeals for ME advocate Nevra Elis
-
Doctors who refuse to engage with administrative work are abandoning their poorest and sickest patients
-
Leslie Lee III, culture critic and Long COVID advocate, dies at 43
-
The future of Medicaid is “really scary” for people with Long COVID
Science
Covid-19
Health
-
U.S. scientists sequence 1,000 genomes from measles, a disease long eliminated with vaccines
-
California clinicians gather for Long COVID forum. Recent guides offer direction.
-
“It felt like a life-or-death choice”: Pregnancy with Long COVID has many unknowns
-
A new aid in the doctor’s office: Introducing the Long COVID Treatment Guide
-
Where have all the Long COVID clinics gone?
-
Six years in, mental health care providers are still uninformed on Long COVID. And it’s making the crisis worse.
-
How do you get people to care about COVID-19? Here’s what I’ve learned as an organizer.
-
Long COVID taught me to slow down and stop trying to meet able-bodied benchmarks
-
Posthumous album of singer Kara Jane released on Severe ME Awareness Day
-
As a linguist, I want to find the words to measure chronic illness